Safeheal SAS raised €35 million (US$39.72 million) in an oversubscribed series C financing round for its temporary ...

Few observers think of CPAP machines as common fare where the med-tech patent wars are concerned, but Resmed Corp. recently ...

Legislators in Washington again are considering a pair of bills that would affect how patents are obtained and sustained ...

Ulcerative colitis, one type of chronic inflammatory bowel disease, is driven by a form of programmed cell death called pyroptosis.

Chronic hypertension in pulmonary arteries leads to their remodeling, making them increasingly resistant and potentially progressing to right heart failure and premature death. Despite advances in ...

With positive phase IIa cardiovascular disease results in hand, Marea Therapeutics Inc. said it is ready to move on to a phase IIb study sometime in the second quarter of 2025. MAR-001, a monoclonal ...

Formosa Pharmaceuticals Inc. and Almac Discovery Ltd. have announced a global licensing agreement for development and commercialization of ALM-401, a first-in-class engineered bispecific antibody-drug ...

Senseonics Holdings Inc. and Sequel Med Tech LLC revealed plans to develop an automated insulin delivery system using the Eversense one-year, implantable continuous glucose monitoring system to ...

Theriva Biologics Inc.’s stroma-targeting oncolytic virus approach yielded positive findings in metastatic pancreatic ductal adenocarcinoma, with the top-line readout of phase IIb data showing VCN-01 ...

Korea Research Institute of Chemical Technology has identified glutaminase inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Researchers from the Access to Advanced Health Institute and collaborating institutions have developed a promising new bivalent vaccine candidate that can protect against both yellow fever and Zika ...

South Korean government and biopharmaceutical industry representatives urged American policymakers May 7 to refrain from imposing tariffs on pharmaceutical imports, and to spare allies if pharma ...